BridgeBio Pharma (BBIO) Q1 2025 Earnings
BridgeBio Pharma reported Q1 2025 revenue of $116.6M (-44.8% YoY), beat analyst consensus of $68.4M by $48.2M. Diluted EPS came in at $-0.88 (-1660.0% YoY), beat the $-1.00 consensus by $0.12.
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about BridgeBio Pharma's Q1 2025 earnings report.
BridgeBio Pharma (BBIO) reported Q1 2025 earnings on April 29, 2025 after market close.
BridgeBio Pharma reported revenue of $116.6M and diluted EPS of $-0.88 for Q1 2025.
Revenue beat the consensus estimate of $68.4M by $48.2M. EPS beat the consensus estimate of $-1.00 by $0.12.
Compared to the same quarter a year prior, revenue declined 44.8% from $211.1M a year earlier and diluted EPS declined 1660.0% from $-0.05.
You can read the 10-Q periodic report (0000950170-25-060314) directly on SEC EDGAR. The filing index links above go to sec.gov.